 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
||
Historic Investment Portfolio
Exits via M&A
M&A
- Afferent (acquired by Merck)
- Alios (acquired by Johnson+Johnson)
- Ambit (acquired by Daiichi Sankyo)
- Ambrx (acquired by Wuxi)
- Artus (acquired by Qiagen)
- Avexis (acquired by Novartis)
- BioFire (acquired by bioMérieux)
- BioXell (acquired by Cosmo)
- Care Innovations (acquired by PRA Health Sciences)
- CGI (acquired by Gilead)
- DVS (acquired by Fluidigm)
- Envoy (acquired by Takeda)
- Flatiron (acquired by Roche)
- Foundation Medicine (acquired by Roche)
- HistoRx (acquired by Genoptix)
- Leukosite (acquired by Millennium)
- Memory (acquired by Roche)
- Miikana (acquired by EntreMed)
- MySugr (acquired by Roche)
- Sequana (acquired by Celera)
- Stratos Genomics (acquired by Roche)
- Syrrx (acquired by Takeda)
- Tripath (acquired by Becton Dickinson)
- Viewics (acquired by Roche)
Historic Investment Portfolio
Exits via IPO
IPOs
- Addex
- Anadys
- Caliper
- Complete Genomics
- Conatus
- CV Therapeutics
- CytomX
- deCode
- Fibrogen, Inc
- Halozyme Therapeutics
- Horizon Discovery
- Pharmasset
- Protein Design Labs, Inc
- Taimed
- TiGenix
- Xenon